Pfizer Inc. (PFE)
Kansas sues Pfizer, saying it misled the public over COVID-19 vaccine
The state of Kansas has filed a lawsuit against Pfizer alleging the company misled the public about the safety and effectiveness of its COVID-19 vaccine including by working to censor critical information on social media.
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products.
Pfizer sued by Kansas for allegedly hiding COVID vaccine risks, making false claims
The lawsuit claims that, beginning shortly after the vaccine's rollout in early 2021, Pfizer concealed evidence that the shot was linked to pregnancy complications, including miscarriage, as well as inflammation in and around the heart.
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit
The U.S. state of Kansas on Monday sued Pfizer , accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness.
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech SE's BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.
Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading Claims
The state of Kansas has reportedly filed a lawsuit against pharmaceutical giant Pfizer, Inc. PFE, accusing the company of violating consumer protection laws related to its COVID-19 vaccine.
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Pfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. In contrast, Merck stock is up 36% over this period.
Is It Too Late to Buy Pfizer Stock?
Pfizer's recent financial performance has some investors questioning its future. The critics aren't entirely wrong -- the pharmaceutical giant does face challenges.
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Shares of Sarepta Therapeutics Inc. SRPT, -1.15% gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial.
Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon
A difficult period for Pfizer might be coming to an end, as serious setbacks and tough Y/Y comps are in the rearview mirror. The first quarter performance of the commercial business exceeded Street expectations, and the company maintained its full-year revenue guidance while slightly increasing the EPS guidance range. The new Chief Strategy and Innovation Officer may lead to changes in business development approach, although his hands may be tied by the debt burden in the near-term.
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Pfizer (PFE) closed at $27.66 in the latest trading session, marking a -1.32% move from the prior day.
